Advances in drug formulation have improved the tolerability of many commonly used agents. Metformin is recommended as initial drug therapy for type 2 diabetes and has proven long-term efficacy and safety. However, gastrointestinal (GI) side-effects of standard, immediate-release (IR) metformin often reduce medication adherence and limit dose titration. A prolonged-release metformin formulation may improve tolerability over its IR counterpart. We report the results of two prospective and two retrospective clinic-based evaluations of the tolerability of metformin in a total of 95 patients intolerant to standard IR metformin assessed over three to six months following a switch from IR to prolonged-release metformin (Glucophage® SR). Between 62% and 100% of patients from the centres tolerated the prolonged-release formulation. Glycaemia following the switch was improved or unchanged. Prolonged-release metformin represents a useful option for patients intolerant of standard IR metformin due to GI side-effects. This improved tolerance of prolonged-release metformin may improve medication adherence and thereby enhance treatment outcomes.
McIntosh A. , Hutchinson A. , Home PD et al. Clinical guidelines and evidence review for Type 2 diabetes: management of blood glucose. Sheffield: ScHARR, University of Sheffield (2001). Available at www.nice.org.uk. Accessed September 2007.
2.
Clinical Guidelines Task Force, International Diabetes Federation.2005Global Guideline for Type 2 Diabetes . Available at www.idf.org. Accessed September 2007.
3.
Nathan DM , Buse JB , Davidson MB et al. Management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes . Diabetologia2006;49:1711-21.
4.
Kahn SE , Haffner SM , Heise MA et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy . N Engl J Med2006;355:2427-43.
5.
Garber AJ , Larsen J. , Schneider SH , Piper BA , Henry D.Simultaneous glyburide/metformin therapy is superior to component monotherapy as an initial pharmacological treatment for type 2 diabetes . Diabetes Obes Metab2002;4:201-8.
6.
Davidson JA , Scheen AJ , Howlett HCTolerability profile of metformin/glibenclamide combination tablets (Glucovance): a new treatment for the management of type 2 diabetes mellitus . Drug Saf2004;27:1205-16.
7.
Ramsdell JW , Grossman JA , Stephens JM , Botteman MF , Arocho R.A short-term cost-of-treatment model for type 2 diabetes: comparison of glipizide gastrointestinal therapeutic system, metformin, and acarbose . Am J Manag Care1999;5:1007-24.
8.
Scarpello JHB.Optimal dosing strategies for maximising the clinical response to metformin in type 2 diabetes . Br J Diabetes Vasc Dis2001;1:28-36.
Timmins P. , Donahue S. , Meeker J. , Marathe P.Steady-state pharmacokinetics of a novel extended-release metformin formulation . Clin Pharmacokinet2005;44:721-9.
11.
Blonde L. , Dailey GE , Jabbour SA , Reasner CA , Mills DJGastrointestinal tolerability of extended-release metformin tablets compared to immediate-release metformin tablets: results of a retrospective cohort study . Curr Med Res Opin2004;20:565-72.
12.
Bailey CJ , Feher MDTherapies for diabetes. Birmingham. Sherborne Gibbs Ltd, 2004;127.
13.
Fujioka K. , Pans M. , Joyal S.Glycemic control in patients with type 2 diabetes mellitus switched from twice-daily immediate-release metformin to a once-daily extended-release formulation . Clin Ther2003;25:515-29.
